UNLABELLED: Oral and intravenous (IV) N-acetylcysteine (NAC) are used for the treatment of acetaminophen poisoning. The objective of this multicenter study was to compare the safety of these two routes of administration. METHODS: We conducted a multicenter chart review of all patients treated with NAC for acetaminophen poisoning. The primary safety outcome was the percentage of patients with NAC-related adverse events. RESULTS: A total of 503 subjects were included in the safety analysis (306 IV-only, 145 oral-only, and 52 both routes). There were no serious adverse events related to NAC for either route. Nausea and vomiting were the most common related adverse events and were more common with oral treatment (23 vs. 9%). Anaphylactoid reactions were more common with IV administration (6 vs. 2%). CONCLUSIONS: IV and oral NAC are generally mild adverse drug reactions.
UNLABELLED: Oral and intravenous (IV) N-acetylcysteine (NAC) are used for the treatment of acetaminophenpoisoning. The objective of this multicenter study was to compare the safety of these two routes of administration. METHODS: We conducted a multicenter chart review of all patients treated with NAC for acetaminophenpoisoning. The primary safety outcome was the percentage of patients with NAC-related adverse events. RESULTS: A total of 503 subjects were included in the safety analysis (306 IV-only, 145 oral-only, and 52 both routes). There were no serious adverse events related to NAC for either route. Nausea and vomiting were the most common related adverse events and were more common with oral treatment (23 vs. 9%). Anaphylactoid reactions were more common with IV administration (6 vs. 2%). CONCLUSIONS: IV and oral NAC are generally mild adverse drug reactions.
Authors: David P Betten; F Lee Cantrell; Stephen C Thomas; Saralyn R Williams; Richard F Clark Journal: Ann Emerg Med Date: 2007-01-08 Impact factor: 5.721
Authors: Fergus Kerr; Andrew Dawson; Ian M Whyte; Nicholas Buckley; Lindsay Murray; Andis Graudins; Betty Chan; Barbara Trudinger Journal: Ann Emerg Med Date: 2005-04 Impact factor: 5.721
Authors: W Stephen Waring; Alexandra F Stephen; Oliver D Robinson; Margaret A Dow; Janice M Pettie Journal: Clin Toxicol (Phila) Date: 2008-07 Impact factor: 4.467
Authors: Mariel R B Betto; Lais F Lazarotto; Tatiane T N Watanabe; David Driemeier; Carlos E Leite; Maria M Campos Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-07-03 Impact factor: 3.000
Authors: Jacqueline A Hawkins-Salsbury; Elizabeth Y Qin; Adarsh S Reddy; Carole A Vogler; Mark S Sands Journal: Exp Neurol Date: 2012-07-28 Impact factor: 5.330